Cardathea can disrupt the $12B cardiac electronic implantable device (CEID) market by making fast, easy, reliable “conduction system pacing” (CSP, the emerging standard) finally possible with its inexpensive electric field imaging (EFI) system. A CEID manufacturer who exclusively owned EFI would gain market share as CEID implantations shift to CSP. A 5% share shift is worth >$1B. Cardathea has already used its EFI in 8 pigs and 14 people.